Botulinum toxin for the management of adult patients with upper motor neuron syndrome

Toxicon

Volumn 54, Issue 5, 2009, Pages 634-638

  Esquenazi, Alberto ^a   Mayer, Nathaniel H ^b   Elia, Antonio E ^c   Albanese, Alberto ^c  

^a Gait and Motion Analysis Laboratory   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Botulinum toxins; Spasticity; Upper motoneuron syndrome

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ARTICLE; AUTONOMIC DYSFUNCTION; CEREBROVASCULAR ACCIDENT; CONTRACTURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; FUNCTIONAL ASSESSMENT; HUMAN; JOINT MOBILITY; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; MUSCLE HYPERTONIA; NAUSEA; PRIORITY JOURNAL; RANGE OF MOTION; SPASTICITY; SYMPTOM; TRAUMATIC BRAIN INJURY; XEROSTOMIA;

ADULT; BOTULINUM TOXINS; HUMANS; MOTOR NEURON DISEASE; MUSCLE SPASTICITY; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; PSYCHOMOTOR PERFORMANCE; UPPER EXTREMITY;

EID: 68849125464     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2009.01.022     Document Type: Article

References (30)

1. Anonymous. Therapy-based rehabilitation services for stroke patients at home. Cochrane Database Syst. Rev. 1 (2003) CD002925
2. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 192 (1964) 540-542
3. Biering-Sorensen F., Nielsen J.B., and Klinge K. Spasticity-assessment: a review. Spinal Cord 44 (2006) 708-722
4. Bohannon R.W., and Smith M.B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys. Ther. 67 (1987) 206-207
5. Brashear A., McAfee A.L., Kuhn E.R., and Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch. Phys. Med. Rehabil. 85 (2004) 705-709
6. Brin M.F. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve 20 Suppl. 6 (1997) S208-S220
7. Cohen M.E., and Marino R.J. The tools of disability outcomes research functional status measures. Arch. Phys. Med. Rehabil. 81 Suppl. 2 (2000) S21-S29
8. Das T.K., and Park D.M. Effect of treatment with botulinum toxin on spasticity. Postgrad. Med. J. 65 (1989) 208-210
9. de Jong L.D., Nieuwboer A., and Aufdemkampe G. The hemiplegic arm: interrater reliability and concurrent validity of passive range of motion measurements. Disabil. Rehabil. 29 (2007) 1442-1448
10. Dengler R., Neyer U., Wohlfarth K., Bettig U., and Janzik H.H. Local botulinum toxin in the treatment of spastic drop foot. J. Neurol. 239 (1992) 375-378
11. Elia, A.E., Filippini, G., Calandrella, D., Albanese, A. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov. Disord., in press.
12. Esquenazi A., Mayer N., and Garreta R. Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait. Am. J. Phys. Med. Rehabil. 87 (2008) 305-310
13. Gracies J.M. Pathophysiology of impairment in patients with spasticity and use of stretch as a treatment of spastic hypertonia. Phys. Med. Rehabil. Clin. N. Am. 12 (2001) 747-768
14. Hinderer S.R., and Gupta S. Functional outcome measures to assess interventions for spasticity. Arch. Phys. Med. Rehabil. 77 (1996) 1083-1089
15. Jackson J.H. On the Anatomical and Physiological Localisation of Movements in the Brain (1875), J. & A. Churchill, London
16. Kotila M., Waltimo O., Niemi M.L., Laaksonen R., and Lempinen M. The profile of recovery from stroke and factors influencing outcome. Stroke 15 (1984) 1039-1044
17. Mayer N.H. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve 20 Suppl. 6 (1997) S1-S13
18. Mayer N.H., and Esquenazi A. Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. Phys. Med. Rehabil. Clin. N. Am. 14 (2003) 855-883
19. Mayer N.H., and Herman R.M. Phenomenology of muscle overactivity in the upper motor neuron syndrome. Eura Medicophys. 40 (2004) 85-110
20. Mayer N.H., Esquenazi A., and Keenan M.A. Assessing and treating muscle overactivity in the upper motoneuron syndrome. In: Zasler N.D., and Zafonte R.D. (Eds). Brain Injury Medicine (2007), Demos, New York 615-653
21. Naumann M., and Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr. Med. Res. Opin. 20 (2004) 981-990
22. O'Brien C.F., Seeberger L.C., and Smith D.B. Spasticity after stroke. Epidemiology and optimal treatment. Drugs Aging 9 (1996) 332-340
23. Penn R.D., Savoy S.M., Corcos D., Latash M., Gottlieb G., Parke B., and Kroin J.S. Intrathecal baclofen for severe spinal spasticity. N. Engl. J. Med. 320 (1989) 1517-1521
24. Platz T., Eickhof C., Nuyens G., and Vuadens P. Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil. Rehabil. 27 (2005) 7-18
25. Sheean G.L. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit?. Curr. Opin. Neurol. 14 (2001) 771-776
26. Sheean G. The pathophysiology of spasticity. Eur. J. Neurol. 9 Suppl. 1 (2002) 3-9
27. Simpson D.M., Gracies J.M., Graham H.K., Miyasaki J.M., Naumann M., Russman B., Simpson L.L., and So Y. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70 (2008) 1691-1698
28. Turkel C.C., Bowen B., Liu J., and Brin M.F. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch. Phys. Med. Rehabil. 87 (2006) 786-792
29. Ward A.B. A summary of spasticity management-a treatment algorithm. Eur. J. Neurol. 9 Suppl. 1 (2002) 48-52
30. Watkins C.L., Leathley M.J., Gregson J.M., Moore A.P., Smith T.L., and Sharma A.K. Prevalence of spasticity post stroke. Clin. Rehabil. 16 (2002) 515-522